9 Meters Biopharma, Inc. is making waves in the biopharmaceutical industry with its focus on delivering treatments for rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. Recent developments include the advancement of its groundbreaking product, Larazotide, an 8-amino acid peptide, which is currently in Phase 3 clinical trial for the treatment of celiac disease. The company is conducting another Phase IIa clinical trial of Larazotide for the treatment of multi-system inflammatory syndrome. In addition, the company is developing Vurolenatide, a long-acting injectable glucagon-like-peptide-1, which is currently in Phase 2 clinical trial to treat short bowel syndrome. Further product offerings include NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina and is determined to continue to break barriers in the world of biopharmaceuticals.
9 Meters Biopharma, Inc.'s ticker is NMTR
The company's shares trade on the NASDAQ stock exchange
They are based in Raleigh, North Carolina
There are 1-10 employees working at 9 Meters Biopharma, Inc.
It is https://9meters.com/
9 Meters Biopharma, Inc. is in the Healthcare sector
9 Meters Biopharma, Inc. is in the Biotechnology industry
The following five companies are 9 Meters Biopharma, Inc.'s industry peers: